-transparent.png){kind=logo}
The ability of azathioprine to reduce the corticosteroid requirements of patients with severe rheumatoid arthritis was tested under double-blind conditions against placebo. After 12 months a significant mean dose reduction of 36% was achieved without undue side-effects. This form of therapy promises to be an advance in the management of severe rheumatoid arthritis.
Related Publications
M Mason, and
H L Currey, and
C G Barnes, and
J F Dunne, and
B L Hazleman, and
I D Strickland
January 2000,
The Cochrane database of systematic reviews,
M Mason, and
H L Currey, and
C G Barnes, and
J F Dunne, and
B L Hazleman, and
I D Strickland
January 2000,
The Cochrane database of systematic reviews,
M Mason, and
H L Currey, and
C G Barnes, and
J F Dunne, and
B L Hazleman, and
I D Strickland
October 1981,
The Medical letter on drugs and therapeutics,
M Mason, and
H L Currey, and
C G Barnes, and
J F Dunne, and
B L Hazleman, and
I D Strickland
October 1982,
Arthritis and rheumatism,
M Mason, and
H L Currey, and
C G Barnes, and
J F Dunne, and
B L Hazleman, and
I D Strickland
October 1981,
Arthritis and rheumatism,
M Mason, and
H L Currey, and
C G Barnes, and
J F Dunne, and
B L Hazleman, and
I D Strickland
November 1971,
British medical journal,
M Mason, and
H L Currey, and
C G Barnes, and
J F Dunne, and
B L Hazleman, and
I D Strickland
November 1969,
Journal of the Iowa Medical Society,
M Mason, and
H L Currey, and
C G Barnes, and
J F Dunne, and
B L Hazleman, and
I D Strickland
June 1988,
Annals of the rheumatic diseases,
M Mason, and
H L Currey, and
C G Barnes, and
J F Dunne, and
B L Hazleman, and
I D Strickland
January 1972,
Scandinavian journal of rheumatology,
M Mason, and
H L Currey, and
C G Barnes, and
J F Dunne, and
B L Hazleman, and
I D Strickland
August 1974,
Postgraduate medical journal,
